Clinical trial · Interventional
Reduced Dissemination of Tumor Cells With Primary Ligation of the Inferior Mesenteric Vein in Rectal Cancer Patients.
Effect of Ligation Sequence of the Inferior Mesenteric Artery and Vein on Circulating Tumor Cells and Survival in Laparoscopic Rectal Cancer Surgery: a Prospective, Multicenter, Randomized Controlled Study (ARVECTS)
NCT05807646CI-TRIAL-00074056not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Effect of ligation sequence of the inferior mesenteric artery and vein on circulating tumor cells and survival in laparoscopic rectal cancer surgery: a prospective, multicenter, randomized controlled study (ARVECTS)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Artery ligation first | Other | — | UNRESOLVED |
| Vein ligation first | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Vein ligation first
- description
- During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
- interventionNames
- Other: Vein ligation first
- type
- ACTIVE_COMPARATOR
- label
- Artery ligation first
- description
- During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
- interventionNames
- Other: Artery ligation first
Primary outcomes (1)
- measure
- The changes of the level of circulating tumor cells in the peripheral blood
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age: 18-75 years; 2. Histopathologically confirmed as rectal adenocarcinoma(tumor located within 15 cm from the anal verge at colonoscopy); 3. Patients with a stage I-III rectal cancer eligible for surgery and R0 resection is expected, patients with pelvic lateral lymph nodes metastasis are ineligible; 4. ECOG score: 0-1; 5. ASA score: I/II/III; 6. Laparoscopic surgery; 7. Informed consent. Exclusion Criteria: 1. Patients who have received preoperative treatment (such as preoperative radiotherapy and chemotherapy); 2. Receiving transanal total mesorectal excision (taTME), specimen extraction through natural lumen (NOSES) ; 3. Recurrent rectal cancer; 4. Simultaneous or metachronous colorectal cancer; 5. Malignant tumors of other organs in the past 5 years or at the same time; 6. The results of preoperative physical examination and imaging examination showed that: (1) the tumor involved the surrounding organs and required combined organ resection; (2) distant metastasis; (3) could not be resected at R0; 7. Pregnant or lactating women; 8. Patients with severe mental disorder; 9. It is not suitable for patients undergoing laparoscopic surgery (such as extensive adhesion caused by previous abdominal surgery or inability to tolerate artificial pneumoperitoneum); 10. History of unstable angina pectoris or myocardial infarction in the past 6 months; 11. Have a history of cerebrovascular accident in the past 6 months; 12. Systemic administration of corticosteroids within 1 month before enrollment; 13. Taking folic acid related drugs within half a year before operation. 14. Severe cardiac insufficiency (FEV1\<50% of predicted values); 15. Emergency surgery.
References
Publications (1)
- DERIVEDPan T, Hu H, Liu C, Zhou HY. Effect of ligation sequence of the inferior mesenteric artery and vein on circulating tumour cells and survival in minimally invasive rectal cancer surgery: study protocol for a randomised controlled trial (ARVECTS study). BMJ Open. 2025 Nov 19;15(11):e098428. doi: 10.1136/bmjopen-2024-098428. PMID 41263842